Skip to content

Application of tramadol and sufentanil combined with propofol in painless gastroscopy in young people

Application of tramadol and sufentanil combined with propofol in painless gastroscopy in young people

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084512
Enrollment
Unknown
Registered
2024-05-20
Start date
2023-10-16
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless gastroscopy

Interventions

Experimental group:The experimental group was given tramadol and sufentanil combined with propofol
control group:The control group was given sufentanil combined with propofol

Sponsors

Xianyang first People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Painless gastroscopy was to be performed in the outpatient department; (2) Young and middle-aged patients (aged 18-45 years); (3) According to the American Society of Anesthesiologists anesthesia Risk assessment table, assess qualified candidates (ASAI ~ Level II); (4) Approved by the Ethics Committee and informed consent of the patient.

Exclusion criteria

Exclusion criteria: (1) Patients with acute respiratory infections, asthma attacks, respiratory failure and other severe respiratory diseases; (2) Patients with uncontrolled malignant hypertension, unstable angina pectoris, myocardial infarction, malignant arrhythmia and other serious cardiovascular and cerebrovascular diseases; (3) Patients with acute upper gastrointestinal bleeding with shock, gastrointestinal obstruction with gastric content retention, etc., easy to cause reflux, aspiration and asphyxia; (4) Patients in a critical state such as shock or extremely weak, cachexia, etc., who cannot be examined; (5) Patients with severe anemia; (6) Patients with serious other systemic diseases; (7) There is coagulation or immune dysfunction (8) pregnancy and breastfeeding women. (9) There is coagulation or immune dysfunction; (10) Patients with opioid addiction or mental illness (11) are allergic to the drugs used in this study.

Design outcomes

Primary

MeasureTime frame
Anesthetic effect ;

Secondary

MeasureTime frame
Mean arterial pressure;Propofol dose ;Adverse events;Heart rate;

Countries

China

Contacts

Public ContactQi Mao

Xianyang first People's Hospital

605353822@qq.com+86 151 2910 8558

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026